A record of what Jitendra Sriram said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on the Pharmaceuticals sector, identifying it as a promising multi-year story. Strong opportunities in CDMO, contract manufacturing, and innovation-led drug development are expected to drive growth in this sector.”
Nifty PharmaBullishCalled 01 Dec 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Jitendra Sriram’s full track record